title: What's new in systemic therapy for endometrial cancer.
abstract: OBJECTIVE
  Endometrial cancer is one of the most common gynecologic cancers. Most women present with early disease that is curable. In women with poor prognostic factors or advanced disease, survival is greatly diminished. Recently there have been several trials of adjuvant treatment and treatment for advanced and recurrent endometrial cancer. These trials of systemic therapy will be reviewed.
  
  
  RESULTS
  Several areas have been the focus of recent literature on systemic therapy for endometrial cancer. These include large phase III trials of multi-agent chemotherapy regimens for advanced and recurrent endometrial cancer, combined chemotherapy and radiotherapy treatments, and novel targeted agents.
  
  
  CONCLUSIONS
  New approaches to combining the traditional adjuvant modalities for high-risk endometrial cancer as well as combining new novel agents with traditional chemotherapeutics will improve patient outcomes.
authors.affiliation: Department of Gynaecologic Oncology, Princess Margaret Hospital, University of Toronto, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada.
authors.forename: Katharina
authors.initials: K
authors.lastname: Kieser
authors.forename: Amit M
authors.initials: AM
authors.lastname: Oza
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D020249:Hormone Replacement Therapy / Q000639:trends; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists